Royalty Pharma plc (RPRX) DCF Valuation

DCF -Bewertung von Royalty Pharma Plc (RPRX)

US | Healthcare | Biotechnology | NASDAQ
Royalty Pharma plc (RPRX) DCF Valuation
  • ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • ✓ Professional Design: Trusted, Industry-Standard Templates
  • ✓ Pre-Built For Quick And Efficient Use
  • ✓ No Expertise Is Needed; Easy To Follow

Royalty Pharma plc (RPRX) Bundle

Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Gewinnen Sie einen Einblick in Ihre Bewertungsanalyse für Royalty Pharma PLC (RPRX) mit unserem ausgefeilten DCF -Taschenrechner! Diese Excel -Vorlage wird mit realen (RPRX-) Daten vorinstalliert, sodass Sie Prognosen und Annahmen anpassen können, um den inneren Wert der Lizenzhauses Pharma Plc genau zu bestimmen.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2020		 AY2
2021		 AY3
2022		 AY4
2023		 AY5
2024		 FY1
2025		 FY2
2026		 FY3
2027		 FY4
2028		 FY5
2029
Revenue 2,122.0 2,289.5 2,237.2 2,354.6 2,264.0 2,303.7 2,344.0 2,385.1 2,426.9 2,469.4
Revenue Growth, % 0 7.89 -2.28 5.24 -3.85 1.75 1.75 1.75 1.75 1.75
EBITDA 1,683.5 1,453.7 928.6 1,887.3 1,292.0 1,481.5 1,507.5 1,533.9 1,560.8 1,588.1
EBITDA, % 79.34 63.5 41.51 80.15 57.07 64.31 64.31 64.31 64.31 64.31
Depreciation 23.1 23.0 5.7 395.1 .0 88.1 89.7 91.2 92.8 94.5
Depreciation, % 1.09 1 0.25344 16.78 0 3.83 3.83 3.83 3.83 3.83
EBIT 1,660.5 1,430.7 922.9 1,492.2 1,292.0 1,393.4 1,417.8 1,442.7 1,467.9 1,493.7
EBIT, % 78.25 62.49 41.25 63.37 57.07 60.49 60.49 60.49 60.49 60.49
Total Cash 1,992.0 2,803.3 2,427.8 495.3 987.2 1,651.8 1,680.7 1,710.2 1,740.2 1,770.6
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables 626.4 682.7 727.9 775.1 27.0
Account Receivables, % 29.52 29.82 32.54 32.92 1.19
Inventories 657.1 .0 .0 .0 .0 142.7 145.2 147.7 150.3 152.9
Inventories, % 30.97 0.0000000437 0.0000000447 0 0 6.19 6.19 6.19 6.19 6.19
Accounts Payable 10.8 5.6 7.9 15.2 13.4 10.8 11.0 11.2 11.4 11.6
Accounts Payable, % 0.50778 0.24547 0.35339 0.64407 0.59055 0.46825 0.46825 0.46825 0.46825 0.46825
Capital Expenditure 2,197.0 .5 2,041.2 .0 .0 .0 .0 .0 .0 .0
Capital Expenditure, % 103.53 0.02284378 91.24 0 0 0 0 0 0 0
Tax Rate, % 35.46 35.46 35.46 35.46 35.46 35.46 35.46 35.46 35.46 35.46
EBITAT 483.1 551.9 171.8 996.0 833.8 606.3 617.0 627.8 638.8 650.0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF 1,430.4 1,171.1 2,175.7 1,351.2 1,580.2 -4.3 694.1 706.3 718.7 731.3
WACC, % 4.91 5.02 4.79 5.33 5.31 5.07 5.07 5.07 5.07 5.07
PV UFCF
SUM PV UFCF 2,394.3
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 746
Terminal Value 24,285
Present Terminal Value 18,964
Enterprise Value 21,358
Net Debt 6,683
Equity Value 14,674
Diluted Shares Outstanding, MM 593
Equity Value Per Share 24.76

What You Will Receive

  • Customizable Excel Template: A fully editable Excel-based DCF Calculator featuring pre-filled real RPRX financials.
  • Actual Data: Historical data alongside forward-looking estimates (highlighted in the yellow cells).
  • Flexible Forecasting: Adjust forecast assumptions such as revenue growth, EBITDA %, and WACC.
  • Instant Calculations: Quickly observe how your inputs affect Royalty Pharma's valuation.
  • Professional Resource: Designed for investors, CFOs, consultants, and financial analysts.
  • Intuitive Design: Organized for clarity and user-friendliness, complete with step-by-step guidance.

Key Features

  • 🔍 Real-Life RPRX Financials: Pre-filled historical and projected data for Royalty Pharma plc.
  • ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
  • 📊 Professional DCF Valuation: Built-in formulas calculate Royalty Pharma’s intrinsic value using the Discounted Cash Flow method.
  • ⚡ Instant Results: Visualize Royalty Pharma’s valuation instantly after making changes.
  • Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.

How It Works

  1. Step 1: Download the Excel file.
  2. Step 2: Review pre-entered Royalty Pharma data (historical and projected).
  3. Step 3: Adjust key assumptions (yellow cells) based on your analysis.
  4. Step 4: View automatic recalculations for Royalty Pharma’s intrinsic value.
  5. Step 5: Use the outputs for investment decisions or reporting.

Why Choose This Calculator for Royalty Pharma plc (RPRX)?

  • Accurate Data: Access to real Royalty Pharma financials ensures trustworthy valuation outcomes.
  • Customizable: Tailor essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
  • Time-Saving: Pre-configured calculations save you the hassle of starting from the ground up.
  • Professional-Grade Tool: Crafted for investors, analysts, and consultants in the pharmaceutical sector.
  • User-Friendly: An intuitive design and clear step-by-step guidance make it accessible for all users.

Who Should Use This Product?

  • Institutional Investors: Develop comprehensive valuation models to assess Royalty Pharma plc (RPRX) investment opportunities.
  • Corporate Development Teams: Evaluate various valuation scenarios to inform strategic decisions.
  • Financial Consultants: Deliver precise valuation analysis and insights for clients interested in Royalty Pharma plc (RPRX).
  • Academic Researchers: Utilize real-time data to study and teach financial modeling techniques.
  • Pharmaceutical Analysts: Gain insights into how companies like Royalty Pharma plc (RPRX) are valued within the biotech sector.

What the Template Contains

  • Pre-Filled Data: Includes Royalty Pharma plc’s historical financials and projections.
  • Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
  • Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
  • Key Financial Ratios: Analyze Royalty Pharma plc’s profitability, efficiency, and leverage.
  • Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
  • Clear Dashboard: Charts and tables summarizing key valuation results.


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.

Es wurden keine passenden Produkte gefunden.